Agile Therapeutics, Inc. announced an agreement with vitaCare Prescription Services to expand patient access and streamline fulfillment for Twirla (levonorgestrel ethinyl estradiol) transdermal system. Agile continues to grow Twirla's presence on telemedicine platforms, including Twentyeight Health, in addition to existing partners like Pandia Health and Nurx as more women choose telemedicine for their contraceptive needs. The Company believes that the Twentyeight Health platform will provide an opportunity for more patients to learn about and access Twirla.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3755 USD | +0.13% | -2.21% | -80.74% |
Mar. 28 | Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024 | |
Mar. 28 | Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q4 Revenue $3.6M | MT |
1st Jan change | Capi. | |
---|---|---|
-80.74% | 2.57M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- AGRX Stock
- News Agile Therapeutics, Inc.
- Agile Therapeutics, Inc. Announces New Agreement with vitaCare Prescription Services to Improve Access to Twirla